Hope for Drug-Resistant Epilepsy Starts Here

Epilepsy affects over 65 million people worldwide, with nearly one-third facing drug-resistant forms that do not respond to traditional medications. For these individuals, the burden of uncontrolled seizures goes beyond medical challenges—it impacts education, employment, and quality of life.

At Aphios Pharma, we’re pioneering a next-generation solution: extended-release cannabidiol (CBD) nanoparticles for the treatment of refractory epilepsy. Powered by our patented SuperFluids™ Polymer Nanosphere (SFS-PNS™) technology, this innovative formulation is designed to increase bioavailability, reduce side effects, and improve seizure control.

Why CBD? Why Now?

CBD is a non-psychoactive component of Cannabis sativa that has demonstrated seizure-reducing effects in multiple clinical trials. While the FDA-approved Epidiolex® was a major milestone, it presents challenges:

• Low oral bioavailability (~6%)
• Twice-daily dosing
• Contains sesame oil, a common allergen

Our solution addresses these limitations through nanoencapsulation.

Our Solution: Nanoencapsulated, Extended-Release CBD

We encapsulate CBD in biodegradable polymers (PLGA or PCL) using our SFS-PNS™ platform. This process improves oral uptake, extends drug release, and eliminates toxic solvents and allergenic ingredients. Benefits include:

✅ Higher bioavailability✅ Once-daily dosing✅ Allergen-free formulation✅ Biodegradable and sterile nanoparticles

Development Timeline

Phase I: Manufacture and test optimized CBD nanoparticles in animal modelsPhase II: Scale production under cGMP, complete preclinical studies, file INDPhase III: Conduct Phase 2/3 clinical trials in partnership with investors and strategic collaborators

Invest in the Future of Epilepsy Care

With an $8 billion global epilepsy market and a large unmet need in drug-resistant patients, our CBD nanoparticle platform offers a unique opportunity for high-impact investment. Backed by preclinical success and strong IP, we are positioned for FDA engagement and clinical advancement.

Let’s work together to deliver relief where it’s needed most.

For Patients and Families

If you or a loved one suffers from drug-resistant epilepsy, we’re working hard to bring a safer, more effective option to you. Our once-daily CBD formulation is being designed to reduce seizures—without the allergens or side effects found in current treatments.

📩 Contact Us: info@aphios.com🌐 Learn more at: www.aphios.com

This product is currently in development and has not yet been approved by the FDA.